Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
25.75
-1.33 (-4.91%)
At close: Jul 13, 2026, 4:00 PM EDT
25.92
+0.17 (0.67%)
After-hours: Jul 13, 2026, 7:33 PM EDT

Legend Biotech Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Legend Biotech stock has a consensus rating of "Buy" and an average price target of $57.17. The average 1-year stock price forecast is 122.02% higher than the current stock price, while the lowest is $27 (+4.85%) and the highest is $86 (+233.98%).

Price Target: $57.17 (+122.02%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$27$57.17$59.5$86
Change+4.85%+122.02%+131.07%+233.98%

Analyst Ratings

The average analyst rating for Legend Biotech stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy999877
Buy555555
Hold222222
Sell000000
Strong Sell000000
Total161616151414

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
J.P. Morgan
J.P. Morgan
Hold
Initiates
$35
HoldInitiates$35+35.92%Jul 13, 2026
RBC Capital
RBC Capital
Buy
Maintains
$64$63
BuyMaintains$64$63+144.66%Jul 7, 2026
Goldman Sachs
Goldman Sachs
Buy
Maintains
$44$41
BuyMaintains$44$41+60.85%Jun 26, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$75
BuyMaintains$75+191.26%Jun 15, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$64
BuyReiterates$64+148.54%Jun 15, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.44B
from 1.03B
Increased by 39.75%
Revenue Next Year
1.81B
from 1.44B
Increased by 25.58%
EPS This Year
0.28
from -1.60
EPS Next Year
1.15
from 0.28
Increased by 309.53%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
68.83M117.01M285.10M627.30M1.03B1.44B
Revenue Growth
-8.23%70.00%143.67%120.03%64.02%39.75%
Gross Profit
68.83M51.64M140.90M392.70M620.80M853.50M
Gross Margin
100.00%44.14%49.42%62.60%60.34%59.36%
Operating Income
-394.02M-458.05M-528.10M-305.10M-136.50M42.79M
Net Income
-403.58M-446.35M-518.30M-177.00M-296.80M8.59M
EPS
-----1.600.28
Forward PE
----150.4391.96
Free Cash Flow
-122.84M-202.66M-496.78M-40.55M-133.99M-15.00M
No. Analysts
-----12
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.5B
Avg1.4B
Low1.4B

Revenue Growth

Revenue Growth202620272028
High
49.7%
Avg
39.7%
Low
33.4%

EPS Forecast

EPS202620272028
High0.28
Avg0.28
Low0.28

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-